These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 21945719

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer.
    Berglund A, Garmo H, Robinson D, Tishelman C, Holmberg L, Bratt O, Adolfsson J, Stattin P, Lambe M.
    Eur J Cancer; 2012 Jan; 48(1):75-84. PubMed ID: 21852113
    [Abstract] [Full Text] [Related]

  • 11. Towards an optimal interval for prostate cancer screening.
    van Leeuwen PJ, Roobol MJ, Kranse R, Zappa M, Carlsson S, Bul M, Zhu X, Bangma CH, Schröder FH, Hugosson J.
    Eur Urol; 2012 Jan; 61(1):171-6. PubMed ID: 21840117
    [Abstract] [Full Text] [Related]

  • 12. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
    Zhu X, van Leeuwen PJ, Bul M, Otto SJ, de Koning HJ, Bangma CH, Schröder FH, Roobol MJ.
    Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.
    Adolfsson J, Garmo H, Varenhorst E, Ahlgren G, Ahlstrand C, Andrén O, Bill-Axelson A, Bratt O, Damber JE, Hellström K, Hellström M, Holmberg E, Holmberg L, Hugosson J, Johansson JE, Petterson B, Törnblom M, Widmark A, Stattin P.
    Scand J Urol Nephrol; 2007 Aug; 41(6):456-77. PubMed ID: 17934985
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Fracture risk in Danish men with prostate cancer: a nationwide register study.
    Abrahamsen B, Nielsen MF, Eskildsen P, Andersen JT, Walter S, Brixen K.
    BJU Int; 2007 Oct; 100(4):749-54. PubMed ID: 17822455
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Ischemic heart disease and stroke before and during endocrine treatment for prostate cancer in PCBaSe Sweden.
    Robinson D, Garmo H, Lindahl B, Van Hemelrijck M, Adolfsson J, Bratt O, Holmberg L, Stattin P.
    Int J Cancer; 2012 Jan 15; 130(2):478-87. PubMed ID: 21387298
    [Abstract] [Full Text] [Related]

  • 20. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men.
    Ørsted DD, Bojesen SE, Nielsen SF, Nordestgaard BG.
    Eur Urol; 2011 Oct 15; 60(4):691-8. PubMed ID: 21705134
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.